Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

Soxradicate Relapse

Financiado

A combined diagnostic and targeted gene therapy platform for brain tumor relapse

Emergence of therapy resistance is a major cause of death following conventional chemotherapy and radiation for children and adults with malignant brain tumors. It is imperative to find novel options to target therapy-resistant br... ver más

29/02/2024

150K€

Presupuesto del proyecto: 150K€

Líder del proyecto

UPPSALA UNIVERSITET No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 2 Participantes

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-02-29

ERC-2022-POC1: ERC PROOF OF CONCEPT GRANTS1 Objective:Objectives:

I+D

Cerrada hace 3 años

0% 100% 100%

2 Participantes

110.00K€ | Lider

UPPSALA UNIVERSITET RESEARCH...

40.00K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

CancerHetero Dissection of tumor heterogeneity in vivo 2M€ Cerrado

PDC2021-121424-I00 BIOPSIA Y TEJIDO EN UN CHIP MAS BIOSENSORES MULTIPLEXADOS IN... 138K€ Cerrado

CNS2023-145726 Herramientas diagnósticas, pronósticas y terapéuticas 200K€ Cerrado

miRToTALL A microRNA-regulated cell death-inducing gene therapy for T-... 150K€ Cerrado

BES-2012-056611 ESTRATEGIAS DE DIRECCIONAMIENTO A TUMORES Y EXPRESION DE TRA... 43K€ Cerrado

SAF2011-23870 MEJORA DE LOS PROTOCOLOS PARA DIAGNOSTICO Y SEGUIMIENTO DE R... 327K€ Cerrado

Duración del proyecto: 18 meses Fecha Inicio: 2022-08-18
Fecha Fin: 2024-02-29

Líder del proyecto

UPPSALA UNIVERSITET No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 150K€

Descripción del proyecto Emergence of therapy resistance is a major cause of death following conventional chemotherapy and radiation for children and adults with malignant brain tumors. It is imperative to find novel options to target therapy-resistant brain tumor populations to save lives. We propose a novel platform providing a prognostic tool and a suicide gene therapy tool using engineered viruses. It involves targeting freshly biopsied cells from brain tumor patients with our strategy in combination with standard therapy to predict risk of patients developing relapse and a gene therapy suicide tool to remove cells causing relapse. Previous suicide gene therapies have only used viruses hitting dividing tumor cells. Our strategy will use an enigneered virus targeting non-dividing tumor cells that we know escape standard therapy. After removing the tumor bulk using standard treatment, we propose to use our virus with a marker for diagnostic purposes or a with a suicide gene that will be activated by a prodrug to eradicate therapy-resistant cells. Prodrug administration before recurrence will eliminate relapsed cells once they start dividing and become dangerous. The impact of our strategy will be high, providing health care professionals with a better tool to identify patients at high risk of developing recurrence. Such patients can receive a better, more tailored treatment that will not only increase their chance of survival but also reduce their time under hospital care and rehabilitation. We protected our strategy with a filed patent and assessed our regulatory needs. We completed a market analysis to evaluate market size and potential benefit for cancer patients. We have disclosed competitors but also potential collaborators that can cofinance and move our strategy forward to in vitro diagnostic device registration and initial clinical trials. In our proposal we will apply for funding covering lab work to test efficacy and safety, help with registration and negotitation strategies.

Conecta tu I+D

Entra hoy

¿Olvidó su contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores